Article

Starting Your Sterile Injectables Program Off On The Right Foot

By Jennifer Quint and Daniel Lenz, Pfizer CentreOne

iStock-1219894397-lab-cleanroom-computer-team

The successful sterile fill and finish of injectable drugs requires the highest levels of operational and quality excellence. Many variables must be considered and few cGMP manufacturing environments are as tightly controlled.  

Due to growing demand, the pharmaceutical industry’s need for sterile injectable (e.g., aseptic and terminal sterilization fill/finish) capacity will likely grow, as will the role of contract development and manufacturing organizations (CDMOs) in delivering such capacity.1  

How can drug sponsors and developers leverage these increasingly strategic commercial fill/finish partnerships? Product development experts Jennifer Quint and Daniel Lenz at Pfizer CentreOne offer their tips on how drug sponsors and developers can put programs on a firmer footing. 

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: